Portola Pharmaceuticals, Inc.A today announced that the U.S. Food and Drug Administration accepted Portola’s New Drug Application granting priority review for betrixaban, an oral, once-daily Factor Xa inhibitor anticoagulant, for extended-duration prophylaxis of venous thromboembolism in acute medically ill patients with risk factors for VTE. A priority review shortens the FDA review timeline to six months from the standard review period of 10 months.